Zacks: Analysts Expect Zynex Inc. (NYSE:ZYXI) Will Announce Quarterly Sales of $12.78 Million

Equities analysts predict that Zynex Inc. (NYSE:ZYXI) will announce sales of $12.78 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Zynex’s earnings. The highest sales estimate is $12.90 million and the lowest is $12.66 million. Zynex reported sales of $9.34 million during the same quarter last year, which indicates a positive year-over-year growth rate of 36.8%. The firm is expected to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Zynex will report full-year sales of $44.09 million for the current year, with estimates ranging from $43.97 million to $44.21 million. For the next year, analysts expect that the business will report sales of $60.21 million, with estimates ranging from $56.51 million to $63.91 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Zynex.

Zynex (NYSE:ZYXI) last released its quarterly earnings results on Tuesday, October 29th. The company reported $0.06 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.06. The business had revenue of $11.82 million during the quarter, compared to analyst estimates of $11.06 million.

Several brokerages have commented on ZYXI. HC Wainwright restated a “buy” rating on shares of Zynex in a research note on Monday, September 23rd. B. Riley reiterated a “buy” rating on shares of Zynex in a research report on Tuesday, October 15th.

ZYXI stock traded up $0.05 during midday trading on Thursday, reaching $10.05. The company had a trading volume of 204,581 shares, compared to its average volume of 236,026. Zynex has a fifty-two week low of $2.58 and a fifty-two week high of $13.10. The stock’s 50 day moving average price is $9.65.

Zynex Company Profile

Zynex, Inc, through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device.

Further Reading: If I purchase shares through a brokerage account, am I the holder of record?

Get a free copy of the Zacks research report on Zynex (ZYXI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with's FREE daily email newsletter.